BUSINESS

• Takeda Jettisons Japan Rights to Obesity Drug OBLEAN after Long Listing Limbo
  July 17, 2018

• Ninlaro Hits Primary Endpoint in Post-Transplant Multiple Myeloma: Takeda
  July 13, 2018

• Otsuka Ventures into Antibody Space with Visterra Buyout
  July 12, 2018

• Kyushu Univ. Spinoff, Nagoya Upstart Launch Joint Research for AMD Treatment
  July 12, 2018

• 1st Patient Dosed in PIII Enfortumab Vedotin Study: Astellas/Seattle Genetics
  July 11, 2018

• Repatha Label Updated in Japan to Add CV Risk Reduction Data
  July 11, 2018

• Takeda Clinches Key US Clearance for Shire Takeover
  July 10, 2018

• Nichi-Iko Ties Up with Sunward for Malaysia, Singapore Biz
  July 10, 2018

• No Major Damage for Drug Makers, Wholesaler Logistics: West Japan Downpours
  July 10, 2018

• Ethical Drug Sales Up 2.6% in May: Crecon
  July 9, 2018

• Eisai/Biogen Say Alzheimer’s Candidate BAN2401 Delivered Positive Data at 18 Month Analysis
  July 9, 2018

• New Takeda Global Headquarters Designed for LGBT Inclusion
  July 9, 2018

• Shionogi Regains Exclusive US Rights to Symproic, Seeking New Partner
  July 9, 2018

• No Drug Breaks 100 Billion Yen Mark in FY2017 Japan Sales Ranking: Jiho Tally
  July 6, 2018

• Use of Digital Health Apps Could Reduce Medical Expenditure by 339 Billion Yen Annually: IQVIA
  July 6, 2018

• Sumitomo Dainippon Files Thiotepa for Conditioning Regimen Prior to Autologous HSCT in Pediatric Solid Tumors
  July 5, 2018

• Pfizer Wringing Hands over PMP Eligibility for Lorlatinib; It Might Earn 1st Conditional OK, but It’s “4th” ALK Inhibitor
  July 5, 2018

• Meiji Holdings Makes Kaketsuken’s Successor Company Its Consolidated Subsidiary
  July 4, 2018

• Single-Dose Flu Drug Xofluza Filed in Taiwan: Shionogi
  July 3, 2018

• Takeda Celebrates Grand Opening for New Global Headquarters
  July 3, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 379
• 380
• 381
• 382
• 383
• 384
• 385
• 386
• 387
• …
• Next ›
• 最終 »